Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Characterizing the contrasting roles of JMJD3 and UTX histone demethylases in T cell acute lymphoblastic leukemia [GSKJ4_RNA-seq]


ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) is an immature hematopoietic malignancy driven mainly by oncogenic activation of NOTCH1 signaling. In this study we chemically inhibited the H3K27me3 demethylase JMJD3 using the GSKJ4 inhibitor and assayed for genome-wide changes in H3K27me3 and JMJD3 enrichment. This piece of data was further integrated to expression changes using RNA sequencing as well as ChIP-Sequencing analysis of H3K27me3 upon genomic knock-down of JMJD3 and UTX. These results, coupled to genomic analysis of primary samples for the genomic status of the UTX gene in T-ALL, helped us to identify a hitherto unknown role of JMJD3 as an oncogenice facilitator in leukemia whereas UTX seems to play a tumor suppressor role. Whole RNA was extracted from 1-5 million primary cells from CUTLL1 human T cell leukemia cells untreated or treated with 2micromolar GSKJ4 using the RNAeasy kit (Qiagen) according to the manufacturer’s protocol. Poly-A+ (magnetic oligodT-containing beads (Invitrogen)) or Ribominus RNA was used for library preparation. cDNA preparation and strand-specific library construction was performed using the dUTP method. Libraries were sequenced on the Illumina HiSeq 2000 using 50bp single-read method. Differential gene expression analysis was performed between knockout vs wild-type background samples. Analysis was performed using DEGseq package leading to very similar conclusions.

ORGANISM(S): Homo sapiens

SUBMITTER: Panagiotis Ntziachristos 

PROVIDER: E-GEOD-56691 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a dismal overall prognosis, including a relapse rate of up to 25%, mainly because of the lack of non-cytotoxic targeted therapy options. Drugs that target the function of key epigenetic factors have been approved in the context of haematopoietic disorders, and mutations that affect chromatin modulators in a variety of leukaemias have recently been identified; however, 'epigenetic' drugs are not currently used for T-  ...[more]

Similar Datasets

2014-10-01 | E-GEOD-56693 | biostudies-arrayexpress
2014-10-01 | GSE56693 | GEO
2014-10-01 | GSE56691 | GEO
2014-10-01 | E-GEOD-56692 | biostudies-arrayexpress
2014-10-01 | E-GEOD-56689 | biostudies-arrayexpress
2014-10-01 | GSE56692 | GEO
2014-10-01 | GSE56689 | GEO
2014-10-01 | E-GEOD-56694 | biostudies-arrayexpress
2014-10-01 | GSE56694 | GEO
2014-10-01 | E-GEOD-56690 | biostudies-arrayexpress